CELC · Celcuity Inc.
$92.00
+5.40 (+6.24%)
At close · Aug 14
Market Cap
$4.50B
Shares
48.93M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$92.00
Open$83.04
Day$83.04–95.56
52W close$45.22–144.98
Avg vol 30d1.5M
Short int10.3M · 21.0% float · 6.8d
Short vol56%
Last earningsAug 13, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Oct 13, 2026
Est · unconfirmed
· in 8 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−12%
below
Price vs 50-day avg
−2%
below
RSI (14)
50
neutral
MACD trend
Positive
52-week position
47%
mid-range
Momentum
relative strength
1-month return
+4%
trailing
6-month return
−13%
trailing
YTD return
−8%
this year
Relative strength
−26%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $94 › 200d $105 — 200d above 50d
Institutional flow
Distributing
-2% holders QoQ · +58 funds added
Insider flow
Distributing
Net -$317.8M over 90 days · 100% sells
Short interest
Falling
20.97% of float · ▼ -8.0% MoM · 6.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
275 holders — near 3-yr high, broad support
Squeeze score
62
elevated · 0–100
Fundamentals
EPS growth
−34%
Y/Y
Free cash flow
$-153.5M
Balance sheet
$28.2M
net cash
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−43%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−12%
Bearish
Price vs 50-day avg
−2%
Neutral
RSI (14)
50
Neutral
MACD trend
Positive
Bullish
52-week position
47%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $94 › 200d $105 — 200d above 50d
Institutional flow
Distributing
-2% holders QoQ · +58 funds added
Insider flow
Distributing
Net -$317.8M over 90 days · 100% sells
Short interest
Falling
20.97% of float · ▼ -8.0% MoM · 6.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
275 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $45
Now $92 · 47%
Range high $145
vs 200-day avg -12%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and short-term investments | $754M | the second quarter of 2026 | — |
| Net cash used in operating activities | $55.4M | the second quarter of 2026 | — |
|
|
|||
| Non-GAAP adjusted net loss non-GAAP | $58.7M | the second quarter of 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP GAAP net loss -$78.86M
+$2.24M Stock-based compensation - Research and development
+$4.66M Stock-based compensation - Selling, general and administrative
+$1.47M Non-cash interest expense
+$332K Non-cash investment (income) expense
+$11.48M Loss on debt extinguishment
= Non-GAAP adjusted net loss -$58.68M
|
|||
| Non-GAAP adjusted net loss per share non-GAAP | $1.07 | the second quarter of 2026 | — |
|
|
|||
| Non-GAAP adjusted net loss per share - basic and diluted non-GAAP | -$1.07 | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP net loss per share - basic and diluted -$1.44
+$0.04 Stock-based compensation - Research and development
+$0.08 Stock-based compensation - Selling, general and administrative
+$0.03 Non-cash interest expense
+$0.01 Non-cash investment (income) expense
+$0.21 Loss on debt extinguishment
= Non-GAAP adjusted net loss per share - basic and diluted -$1.07
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CELC
this stock
Celcuity Inc.
|
$4.50B | -7.8% | — | — | 21.0% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CELC | -0.8% | +4.1% | -12.5% | +6.5% | -7.8% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -1.2% | -0.4% | -26.3% | +2.6% | -21.6% |
Key facts
CIK
1603454
CUSIP
15102K100
13F (30d)
263 filings
262 filers
Visit website
Investor relations